June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Treatment Efficacy of Dual Release of Aflibercept and Dexamethasone from a Single Hydrogel Drug Delivery System in a Laser-induced Choroidal Neovascularization Model
Author Affiliations & Notes
  • Kayla Rudeen
    Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, United States
  • Wenqiang Liu
    Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, United States
  • Katherine L. Lydon
    Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, United States
  • Sabrina J.K. Derwent
    Loyola Academy, Wilmette, Illinois, United States
  • William F Mieler
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Jennifer J Kang-Mieler
    Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Kayla Rudeen, None; Wenqiang Liu, None; Katherine Lydon, None; Sabrina Derwent, None; William Mieler, None; Jennifer Kang-Mieler, Biodegradable microsphere-hydrogel ocular drug delivery system (P)
  • Footnotes
    Support  NIH NEI EY029298
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 277. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kayla Rudeen, Wenqiang Liu, Katherine L. Lydon, Sabrina J.K. Derwent, William F Mieler, Jennifer J Kang-Mieler; Treatment Efficacy of Dual Release of Aflibercept and Dexamethasone from a Single Hydrogel Drug Delivery System in a Laser-induced Choroidal Neovascularization Model. Invest. Ophthalmol. Vis. Sci. 2021;62(8):277.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There is a growing subset of age-related macular degeneration patients that do not successfully respond to a monthly monotherapy treatment of anti-vascular endothelial growth factor (VEGF). Recent studies suggest that this subset may respond to a combination therapy of corticosteroid and anti-VEGF. The current combination therapy is administered in separate injections where anti-VEGF injections are repeated monthly/bimonthly. Recently, we developed a single drug delivery system that can release dexamethasone (DEX) and aflibercept (AFL) simultaneously. This study was to determine the treatment efficacy of DEX and AFL released from a single drug delivery system (DDS) in a choroidal neovascularization (CNV) rodent model.

Methods : AFL and DEX were encapsulated into poly(lactic-co-glycolic acid) particles that were embedded into a single thermoresponsive hydrogel DDS. CNV lesions were created by laser photocoagulation (50um, 0.5W) in Long-Evans rats. Animals were randomly assigned into: control (no treatment), blank-DDS (5ul, no drugs), bolus AFL intravitreal (IVT) injections (5ul, 10ug, bimonthly), AFL-DDS (5ul, 1.5ug), AFL+DEX-DDS (5ul, 1.5ug, 20ug, respectively), and DEX-DDS (5ul, 20ug). At week 0 (14 days after the laser induction), treatment was administered. Fluorescein angiography (FA) was obtained at weeks 0, 2, 6, 10, 14, 18 and 22. Multi-Otsu Thresholding was used to quantify lesion area to determine treatment efficacy.

Results : Before the treatment, FA confirmed that CNV lesions were fully developed. At week 14, increases in lesion size were seen in control(10±8%), while slight decreases were seen in blank-DDS(-1±8%), bolus AFL injections(-3±7%), and DEX-DDS(-5±5%), and larger decreases were seen in AFL-DDS(-21±5%), and AFL+DEX-DDS(-33±5%). At week 22, decreases were seen in bolus AFL injections(-11±7%), DEX-DDS(-12±7%), AFL-DDS(-33±4%), and AFL+DEX-DDS (-30±7%), and increases were seen in control(2±8%) and blank DDS(4±10%).

Conclusions : The combination treatment of AFL and DEX released from a single DDS delivered a lower amount of overall aflibercept compared to bolus injection, with improved treatment efficacy. [MOU1] The study suggests that a combination treatment may be a viable alternative for non-responsive patients.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×